Homepage Top Section2

Under the deal, Astellas US Holding wholly-owned subsidiary Asilomar Acquisition will acquire Audentes by paying $60 per share in cash. Audentes chairman and CEO Matthew Patterson said: “With

The new supplemental Biologics License Application (sBLA) for Keytruda, which has been accepted by the FDA is for the treatment of patients having Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle

The NDA has been accepted for the priority review of selective fibroblast growth factor receptor (FGFR) inhibitor pemigatinib to treat patients with previously treated, locally advanced or metastatic

In this connection, Ferring Pharmaceuticals has launched a new company FerGene, which will focus on the global development and US commercialisation of nadofaragene firadenovec. The gene therapy is

As per the terms of the deal, Novartis has offered to buy the US-based biopharmaceutical company for $85.00 per share in cash. Headquartered in Parsippany, New Jersey, The

Calquence, which is a next-generation selective inhibitor of Bruton’s tyrosine kinase (BTK), binds covalently to BTK to inhibit its activity. The FDA approval was based on data from

Daratumumab is a first-in-class biologic designed to target CD38, a surface protein that is highly expressed across multiple myeloma cells, regardless of disease stage. Daratumumab is considered to

In this regard, the companies will make use of GalXC, an RNA interference (RNAi) technology platform developed by Dicerna, for the discovery of new therapies. The collaboration will

Fetroja has been approved for patients 18 years of age or older who have limited or no alternative treatment options to treat cUTI, including pyelonephritis. It can be